ALTAIR NANOTECHNOLOGIES INC. (NasdaqSC: ALTI)

Dear Readers,

Once again, we are privileged to bring to you compelling information about Altair Nanotechnologies Inc. (NasdaqSC: ALTI), the dynamic NANOTECHNOLOGY company that we’ve been following for years.  ALTI remains quite possibly one of the most popular companies we’ve featured in our long history at StockUpTicks.com after a meteoric rise that brought profits to investors in the know.

As most of our readers know (or should know), nanotechnology is the science of the very small and informed minds in the government and private sectors believe that this new science can change lives in ways that parallel the advent of the Internet.  We’ve published exhaustively on the subject because we subscribe to that opinion as well, offering our readers FREE RESEARCH (click here) on Nanotech info as well while searching out intriquing companies in this sector.

Today we bring to you a recent news releaese regarding two new patents filed by Altair that will extend its intellectual property protection for its drug delivery systems.  Read on!

For our intitial profile on ALTI click here
For a full introductory report on nanotechnology by analyst, Randy Lewis click here
For Current News and Stock Price info on ALTI: click here
 
 

***  Recent News From Altair ***

Press Release 
Source: Altair Nanotechnologies, Inc. 
Tuesday July 27, 8:00 am ET
 

RENO, NV--(MARKET WIRE)--Jul 27, 2004 -- Altair Nanotechnologies, Inc. (NasdaqSC:ALTI - News) today announced that it filed two new patent applications, which extend the company's intellectual property protection for its TiNano Spheres(TM) drug delivery system.

Recent laboratory testing results show the ability to control the level of loading of drugs onto and into the TiNano Spheres, which provides for high drug and chemical loading levels. This capability is important for developing a broad platform of drug delivery systems that can address a multitude of market opportunities. Testing also confirmed that drugs loaded into the TiNano Spheres delivery system matrix can be released at significant therapeutic concentrations. Additional laboratory testing indicated that TiNano Spheres resist crushing, making "street" methods commonly used to abuse drugs like amphetamines or pain management drugs and narcotics difficult or impossible.

Altair continues discussions with potential market partners interested in novel drug delivery systems or companies seeking to extend product life cycles of existing drugs. Altair is targeting markets for use of its TiNano Spheres technology, which uses rigid, hollow ceramic structures, as a drug delivery platform for pain management, inflammation, coronary indications, analgesia and microbial infection. The TiNano Spheres drug delivery platform has the advantage of using materials such as titanium dioxide, which are recognized as being biologically benign and safe. The Freedonia Group estimates that the market for drug delivery systems is approximately $54 billion in the U.S.

"We are confident that Altair has reached a watershed point in building a viable life sciences capability," commented Altair Nanotechnologies President Dr. Rudi E. Moerck. "Our scientists have made significant progress with our lead drug candidate and novel drug delivery system. Our sales and marketing strategy is to continue developing key market partnerships as we expand our product capabilities and pipeline in the Life Sciences Division."

ALTAIR NANOTECHNOLOGIES INC.

Although an emerging field, Nanotechnology is already having a unique impact on several industry sectors. Altair Nanotechnologies is positioning itself through product innovation to become a leading supplier of nanomaterial technology and nanomaterials worldwide. Altair owns robust proprietary technology platforms for manufacturing a variety of crystalline and non-crystalline nano-materials of unique structure, performance, quality and cost. Altair has installed semi-works capability with a capacity to produce hundreds of tons of nano-materials.

The company is organized into two divisions: Life Sciences and Performance Materials. The Life Sciences Division is pursuing market applications in pharmaceuticals, drug delivery, dental materials, cosmetics and other medical markets. The Performance Materials Division is pursuing market applications in paints and coatings (titanium pigments and thermal spray coatings), process technologies (titanium metal manufacturing, catalysts and water treatment), alternative energy (high performance batteries, fuel cell and photovoltaics) and other high performance material applications. For additional information on Altair and its nano-materials, visit www.altairnano.com

Altair Nanotechnologies, Inc.®, Altair Nanomaterials(TM), TiNano®, RenaZorb(TM), NanoCheck(TM), TiNano Spheres(TM), No Defeat(TM) and the Hydrochloride Pigment Process(TM) are trademarks or registered trademarks of Altair Nanotechnologies, Inc.

Forward-Looking Statements

This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the company's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that Altair's numerous development stage products including TiNano Spheres(TM) will not be developed to the point of commercialization or that, even if commercialized, no market will exist for such products or Altair will fail to effectively market to customers in a market, that Altair will be unable to enter into license agreements regarding its pigment process (AHPP), TiNano Spheres(TM), RenaZorb(TM) or other developing products, that even if Altair enters into such license agreements, short-term revenues from such agreements will not be sufficient to fund Altair's operations in the short run, and that animal testing or future testing on TiNano Spheres(TM), RenaZorb(TM) or other products of the company will not be successful and that development will need to be terminated. In general, Altair is, and expects to be in the immediate future, dependent upon funds generated from sales of securities, grants, testing agreements, and licensing agreements to fund its testing, development and ongoing operations. If the company is unable to continue to raise significant funding through such methods, it may be unable to continue as a going concern. In addition, other risks are identified in the company's most recent Annual Report on Form 10-K, as filed with the SEC. Such forward-looking statements speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.

-end

     For Additional Information:
     Marty Tullio or Mark Tullio
     McCloud Communications, LLC
     949.566.9860
     marty@mccloudcommunications.com
     mark@mccloudcommunications.com
 
 

*** A Snapshot Of The Financials ***

 Statistics: 
· Nasdaq symbol: ALTI 
· Fiscal year end: Dec. 31 
· Market Cap: $72.6 M 
· Recent price: $ 1.49 
· Common shares outstanding: 48.7M (as of May13, 2004)
· Float: 34.6 M 

Sectors: Chemical & Specialty Chemical 
Potential portfolio matches: Alternative, Growth, Momentum, Theme 
 

***  CONTACT ***

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Safe Harbor Statement: Statements contained in this document, including those pertaining to estimates and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. 

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  Past performance is no guarantee of future results. This report is for information purposes only and should not be used as the basis for any investment decision.  MP has received 20,000 dollars from Altair for preparation and distribution of this report.  This compensation constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - 1920 Main Street SUite 980 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice.  This information is neither a solicitation to buy nor an offer to sell securities.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.   The opinions contained herein reflect our current judgment and are subject to change without notice.  MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.   Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.